ID: ALA4292141

Max Phase: Preclinical

Molecular Formula: C22H20Cl2O3

Molecular Weight: 403.31

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccc(/C=C2\CCC/C(=C\c3ccc(Cl)cc3Cl)C2=O)cc1OC

Standard InChI:  InChI=1S/C22H20Cl2O3/c1-26-20-9-6-14(11-21(20)27-2)10-16-4-3-5-17(22(16)25)12-15-7-8-18(23)13-19(15)24/h6-13H,3-5H2,1-2H3/b16-10+,17-12+

Standard InChI Key:  CENRKQBOZYVLLE-JTCWOHKRSA-N

Associated Targets(Human)

SW-620 52400 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

A549 127892 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HT-1080 3966 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MCF7 126967 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

NHDF 1164 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 403.31Molecular Weight (Monoisotopic): 402.0789AlogP: 6.23#Rotatable Bonds: 4
Polar Surface Area: 35.53Molecular Species: NEUTRALHBA: 3HBD: 0
#RO5 Violations: 1HBA (Lipinski): 3HBD (Lipinski): 0#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: CX LogP: 6.49CX LogD: 6.49
Aromatic Rings: 2Heavy Atoms: 27QED Weighted: 0.57Np Likeness Score: -0.65

References

1. Leong SW, Chia SL, Abas F, Yusoff K..  (2018)  Asymmetrical meta-methoxylated diarylpentanoids: Rational design, synthesis and anti-cancer evaluation in-vitro.,  157  [PMID:30138803] [10.1016/j.ejmech.2018.08.039]

Source